{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:23:55Z","timestamp":1791289435774,"version":"4.3.0"},"reference-count":231,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Schizophrenia (SCZ) is a complex, comprehensible mental condition that creates alienation from reality. SCZ is a mental disease, which is marked by progressive deficits in working memory, attention, and executive functioning. Because the disease\u2019s etiology is unknown, current psychotherapy and pharmacological treatments merely treat symptoms and do not provide a cure. SCZ symptoms include hallucinations, delusions, disorganized behavior, and lack of desire. Long-term use of antipsychotic (antagonists at multiple G-protein-coupled receptors) (mGPCR antagonists) medicines for therapy has negative health consequences and discourages patients from taking regular medication. Ancient herbal therapies are regaining popularity in disease management due to their natural origins, less side effects, and cost-effectiveness. The various types of phytochemicals include alkaloids, glycosides, polyphenols, terpenes and terpenoids, phytosterols, cannabinoids, and carotenoids could be used as mGPCR antagonists. In this review, we documented the possibility of employing natural compounds as an alternative therapy to treat schizophrenia-related symptoms and cognitive impairments.<\/jats:p>","DOI":"10.1007\/s00210-025-04351-0","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:55:29Z","timestamp":1749786929000},"page":"15231-15255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management"],"prefix":"10.1007","volume":"398","author":[{"given":"Alaa","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya M.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"A. Rabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3179-3352","authenticated-orcid":false,"given":"Riham A.","family":"El-Shiekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"El-Dessouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"4351_CR1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/eip.12861","volume":"14","author":"L Abrahamyan Empson","year":"2020","unstructured":"Abrahamyan Empson L et al (2020) Urbanicity: The need for new avenues to explore the link between urban living and psychosis. Early Interv Psychiatry 14:398\u2013409","journal-title":"Early Interv Psychiatry"},{"key":"4351_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3934\/Neuroscience.2023002","volume":"10","author":"R Ahmad","year":"2023","unstructured":"Ahmad R et al (2023) Brain-derived neurotrophic factor (BDNF) in schizophrenia research: a quantitative review and future directions. AIMS Neurosci 10:5\u201332","journal-title":"AIMS Neurosci"},{"key":"4351_CR3","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1007\/s11356-022-22409-x","volume":"30","author":"KF Alsharif","year":"2023","unstructured":"Alsharif KF et al (2023) Therapeutic antischizophrenic activity of prodigiosin and selenium co-supplementation against amphetamine hydrochloride-induced behavioural changes and oxidative, inflammatory, and apoptotic challenges in rats. Environ Sci Pollut Res 30:7987\u20138001","journal-title":"Environ Sci Pollut Res"},{"key":"4351_CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neubiorev.2016.10.004","volume":"76","author":"D Amato","year":"2017","unstructured":"Amato D, Beasley CL, Hahn MK, Vernon AC (2017) Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neurosci Biobehav Rev 76:317\u2013335","journal-title":"Neurosci Biobehav Rev"},{"key":"4351_CR5","doi-asserted-by":"crossref","unstructured":"an der Heiden W, H\u00e4fner H (2000) The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 250: 292-303","DOI":"10.1007\/s004060070004"},{"key":"4351_CR6","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.3390\/ijms25179371","volume":"25","author":"SA Anghel","year":"2024","unstructured":"Anghel SA et al (2024) Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response. Int J Mol Sci 25:9371","journal-title":"Int J Mol Sci"},{"key":"4351_CR7","doi-asserted-by":"crossref","unstructured":"Asakura M et al (2024) Anthocyanins as potent inhibitors of pentosidine synthesis: Antioxidant-mediated effects. Biochem Biophys Res Commun 740","DOI":"10.1016\/j.bbrc.2024.151007"},{"key":"4351_CR8","doi-asserted-by":"crossref","unstructured":"Asgharian P et al (2022) Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update. Frontiers in Pharmacology 13","DOI":"10.3389\/fphar.2022.926607"},{"key":"4351_CR9","unstructured":"Association AP (2019) American psychiatric association"},{"key":"4351_CR10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1440-1819.2005.01432.x","volume":"59","author":"M Atmaca","year":"2005","unstructured":"Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Kirtas O (2005) The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci 59:652\u2013656","journal-title":"Psychiatry Clin Neurosci"},{"key":"4351_CR11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40261-024-01377-9","volume":"44","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A (2024) Current findings and potential mechanisms of KarXT (xanomeline\u2013trospium) in schizophrenia treatment. Clin Drug Investig 44:471\u2013493","journal-title":"Clin Drug Investig"},{"key":"4351_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12991-021-00348-0","volume":"20","author":"M Bahta","year":"2021","unstructured":"Bahta M, Ogbaghebriel A, Russom M, Tesfamariam EH, Berhe T (2021) Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study. Ann Gen Psychiatry 20:27","journal-title":"Ann Gen Psychiatry"},{"key":"4351_CR13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.schres.2012.02.004","volume":"137","author":"Y Bao","year":"2012","unstructured":"Bao Y et al (2012) Low maternal retinol as a risk factor for schizophrenia in adult offspring. Schizophr Res 137:159\u2013165","journal-title":"Schizophr Res"},{"key":"4351_CR14","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1007\/s12035-021-02703-4","volume":"59","author":"NM Beeraka","year":"2022","unstructured":"Beeraka NM, Avila-Rodriguez MF, Aliev G (2022) Recent reports on redox stress-induced mitochondrial DNA variations, neuroglial interactions, and NMDA receptor system in pathophysiology of schizophrenia. Mol Neurobiol 59:2472\u20132496","journal-title":"Mol Neurobiol"},{"key":"4351_CR15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/metabo10040129","volume":"10","author":"RD Beger","year":"2020","unstructured":"Beger RD, Schmidt MA, Kaddurah-Daouk R (2020) Current concepts in pharmacometabolomics, biomarker discovery, and precision medicine. Metabolites 10:129","journal-title":"Metabolites"},{"key":"4351_CR16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/antiox12020280","volume":"12","author":"P Bellavite","year":"2023","unstructured":"Bellavite P (2023) Neuroprotective potentials of flavonoids: Experimental studies and mechanisms of action. Antioxidants 12:280","journal-title":"Antioxidants"},{"key":"4351_CR17","volume-title":"The role of DTNBP1\/dysbindin-1 in schizophrenia","author":"E Belu\u017ei\u0107","year":"2021","unstructured":"Belu\u017ei\u0107 E (2021) The role of DTNBP1\/dysbindin-1 in schizophrenia. University of Rijeka, Department of Biotechnology"},{"key":"4351_CR18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jpsychires.2024.09.003","volume":"179","author":"B Ben-Azu","year":"2024","unstructured":"Ben-Azu B et al (2024) Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action. J Psychiatr Res 179:141\u2013155","journal-title":"J Psychiatr Res"},{"key":"4351_CR19","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.3390\/ijms23115968","volume":"23","author":"M Bia\u0142o\u0144","year":"2022","unstructured":"Bia\u0142o\u0144 M, W\u0105sik A (2022) Advantages and limitations of animal schizophrenia models. Int J Mol Sci 23:5968","journal-title":"Int J Mol Sci"},{"key":"4351_CR20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn.2017.125","volume":"18","author":"R Birnbaum","year":"2017","unstructured":"Birnbaum R, Weinberger DR (2017) Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci 18:727\u2013740","journal-title":"Nat Rev Neurosci"},{"key":"4351_CR21","volume-title":"Dementia praecox or the group of schizophrenias","author":"E Bleuler","year":"1911","unstructured":"Bleuler E (1911) Dementia praecox or the group of schizophrenias. International Universities Press, Oxford, England"},{"key":"4351_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2016.02.019","volume":"91","author":"T Bordia","year":"2016","unstructured":"Bordia T, Perez XA, Heiss J, Zhang D, Quik M (2016) Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias. Neurobiol Dis 91:47\u201358","journal-title":"Neurobiol Dis"},{"key":"4351_CR23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41386-024-01977-1","volume":"50","author":"C Brakatselos","year":"2024","unstructured":"Brakatselos C et al (2024) Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. Neuropsychopharmacology 50:388\u2013400","journal-title":"Neuropsychopharmacology"},{"key":"4351_CR24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2018.03.012","volume":"199","author":"A Breier","year":"2018","unstructured":"Breier A et al (2018) Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res 199:395\u2013402","journal-title":"Schizophr Res"},{"key":"4351_CR25","doi-asserted-by":"crossref","first-page":"915691","DOI":"10.1155\/2013\/915691","volume":"2013","author":"N Brondino","year":"2013","unstructured":"Brondino N et al (2013) A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. Evid Based Complement Alternat Med 2013:915691","journal-title":"Evid Based Complement Alternat Med"},{"key":"4351_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mrdd.10004","volume":"8","author":"AS Brown","year":"2002","unstructured":"Brown AS, Susser ES (2002) In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev 8:51\u201357","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"4351_CR27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3892\/etm.2020.9340","volume":"20","author":"M Budisteanu","year":"2020","unstructured":"Budisteanu M et al (2020) Predictive factors in early onset schizophrenia. Exp Ther Med 20:210","journal-title":"Exp Ther Med"},{"key":"4351_CR28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.irn.2023.05.013","volume":"171","author":"S Bulnes","year":"2023","unstructured":"Bulnes S, Pico-Gallardo M, Bengoetxea H, Lafuente JV (2023) Effects of curcumin nanodelivery on schizophrenia and glioblastoma. Int Rev Neurobiol 171:163\u2013203","journal-title":"Int Rev Neurobiol"},{"key":"4351_CR29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.neuron.2014.07.028","volume":"83","author":"JH Cabungcal","year":"2014","unstructured":"Cabungcal JH et al (2014) Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 83:1073\u20131084","journal-title":"Neuron"},{"key":"4351_CR30","doi-asserted-by":"crossref","first-page":"114626","DOI":"10.1016\/j.fct.2024.114626","volume":"187","author":"EJ Calabrese","year":"2024","unstructured":"Calabrese EJ et al (2024) RUTIN, a widely consumed flavonoid, that commonly induces hormetic effects. Food Chem Toxicol 187:114626","journal-title":"Food Chem Toxicol"},{"key":"4351_CR31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.psychres.2017.11.006","volume":"259","author":"B Cao","year":"2018","unstructured":"Cao B et al (2018) Association between B vitamins and schizophrenia: A population-based case-control study. Psychiatry Res 259:501\u2013505","journal-title":"Psychiatry Res"},{"key":"4351_CR32","unstructured":"Castro Zamparella T, Balaszczuk V, C\u00e1ceres M (2022) Study of neuroprotective factors mediated by Omega 3 and cognitive stimulation against amnesic mild cognitive impairment in patients residents of the city of C\u00f3rdoba, Argentina. 67th Annual Meeting of the Argentine Society of Clinical Research; 70th Annual Meeting of the Argentine Society of Immunology & 3rd Franco-Argentine Congress of Immunology: 229-229"},{"key":"4351_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41537-020-0105-9","volume":"6","author":"M Caton","year":"2020","unstructured":"Caton M, Ochoa ELM, Barrantes FJ (2020) The role of nicotinic cholinergic neurotransmission in delusional thinking. NPJ Schizophr 6:16","journal-title":"NPJ Schizophr"},{"key":"4351_CR34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/schbul\/sbac106","volume":"49","author":"AM Cavichioli","year":"2023","unstructured":"Cavichioli AM, Santos-Silva T, Grace AA, Guimar\u00e3es FS, Gomes FV (2023) Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats. Schizophr Bull 49:68\u201377","journal-title":"Schizophr Bull"},{"key":"4351_CR35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.carbpol.2011.06.083","volume":"87","author":"J Chen","year":"2012","unstructured":"Chen J, Zhang T, Jiang B, Mu W, Miao M (2012) Characterization and antioxidant activity of Ginkgo biloba exocarp polysaccharides. Carbohydr Polym 87:40\u201345","journal-title":"Carbohydr Polym"},{"key":"4351_CR36","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/14786419.2020.1869968","volume":"36","author":"V Chintha","year":"2022","unstructured":"Chintha V, Wudayagiri R (2022) Isolation and neuroprotective prospective of novel bioactive compound \u201c3-(3,4-dimethoxyphenyl)-1-(4-methoxyphenyl) prop-2-en-1-one\u201d against ketamine-induced cognitive deficits in schizophrenia: an experimental study. Nat Prod Res 36:1352\u20131358","journal-title":"Nat Prod Res"},{"key":"4351_CR37","doi-asserted-by":"crossref","first-page":"585742","DOI":"10.3389\/fpsyt.2021.585742","volume":"12","author":"Z Choudhury","year":"2021","unstructured":"Choudhury Z, Lennox B (2021) Maternal immune activation and schizophrenia\u2013evidence for an immune priming disorder. Front Psych 12:585742","journal-title":"Front Psych"},{"key":"4351_CR38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0091-3057(01)00648-7","volume":"71","author":"I-W Chung","year":"2002","unstructured":"Chung I-W et al (2002) Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy. Pharmacol Biochem Behav 71:191\u2013195","journal-title":"Pharmacol Biochem Behav"},{"key":"4351_CR39","first-page":"808","volume":"5","author":"BA Clementz","year":"2020","unstructured":"Clementz BA et al (2020) Testing psychosis phenotypes from bipolar\u2013schizophrenia network for intermediate phenotypes for clinical application: biotype characteristics and targets. Biol Psychiatry: Cognitive Neurosci Neuroimaging 5:808\u2013818","journal-title":"Biol Psychiatry: Cognitive Neurosci Neuroimaging"},{"key":"4351_CR40","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1038\/s41380-020-0654-3","volume":"26","author":"I Cleynen","year":"2021","unstructured":"Cleynen I et al (2021) Genetic contributors to risk of schizophrenia in the presence of a 22q11. 2 deletion. Mol Psychiatry 26:4496\u20134510","journal-title":"Mol Psychiatry"},{"key":"4351_CR41","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/schbul\/sbs076","volume":"38","author":"JT Coyle","year":"2012","unstructured":"Coyle JT (2012) NMDA receptor and schizophrenia: a brief history. Schizophr Bull 38:920\u2013926","journal-title":"Schizophr Bull"},{"key":"4351_CR42","doi-asserted-by":"crossref","first-page":"6640206","DOI":"10.1155\/2021\/6640206","volume":"2021","author":"AS Curpan","year":"2021","unstructured":"Curpan AS, Luca A-C, Ciobica A (2021) Potential novel therapies for neurodevelopmental diseases targeting oxidative stress. Oxid Med Cell Longev 2021:6640206","journal-title":"Oxid Med Cell Longev"},{"key":"4351_CR43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02867671","volume":"18","author":"B D'Souza","year":"2003","unstructured":"D\u2019Souza B, D\u2019Souza V (2003) Oxidative injury and antioxidant vitamins E and C in Schizophrenia. Indian J Clin Biochem 18:87\u201390","journal-title":"Indian J Clin Biochem"},{"key":"4351_CR44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00213-005-0117-1","volume":"182","author":"GN Dakhale","year":"2005","unstructured":"Dakhale GN, Khanzode SD, Khanzode SS, Saoji A (2005) Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology 182:494\u2013498","journal-title":"Psychopharmacology"},{"key":"4351_CR45","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1016\/j.sjbs.2021.08.036","volume":"28","author":"S Datta","year":"2021","unstructured":"Datta S et al (2021) Wonder or evil?: multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals. Saudi J Biol Sci 28:7290\u20137313","journal-title":"Saudi J Biol Sci"},{"key":"4351_CR46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/dta.1425","volume":"5","author":"S Deiana","year":"2013","unstructured":"Deiana S (2013) Medical use of cannabis. Cannabidiol: A new light for schizophrenia? Drug Test Anal 5:46\u201351","journal-title":"Drug Test Anal"},{"key":"4351_CR47","doi-asserted-by":"crossref","first-page":"790213","DOI":"10.3389\/fnmol.2021.790213","volume":"14","author":"LA Desouza","year":"2021","unstructured":"Desouza LA et al (2021) The hallucinogenic serotonin2A receptor agonist, 2, 5-dimethoxy-4-iodoamphetamine, promotes cAMP response element binding protein-dependent gene expression of specific plasticity-associated genes in the rodent neocortex. Front Mol Neurosci 14:790213","journal-title":"Front Mol Neurosci"},{"key":"4351_CR48","doi-asserted-by":"crossref","first-page":"104208","DOI":"10.1016\/j.nbd.2018.06.020","volume":"131","author":"SJ Dienel","year":"2019","unstructured":"Dienel SJ, Lewis DA (2019) Alterations in cortical interneurons and cognitive function in schizophrenia. Neurobiol Dis 131:104208","journal-title":"Neurobiol Dis"},{"key":"4351_CR49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/02537176211033331","volume":"44","author":"D Dinakaran","year":"2022","unstructured":"Dinakaran D, Sreeraj VS, Venkatasubramanian G (2022) Role of Curcumin in the Management of Schizophrenia: A Narrative Review. Indian J Psychol Med 44:107\u2013113","journal-title":"Indian J Psychol Med"},{"key":"4351_CR50","unstructured":"DiPiro JT et al (2014) Pharmacotherapy: a pathophysiologic approach. 9th Edition. McGraw-Hill Education"},{"key":"4351_CR51","doi-asserted-by":"crossref","first-page":"12463","DOI":"10.1021\/acs.jmedchem.4c00537","volume":"67","author":"M Dorogan","year":"2024","unstructured":"Dorogan M, Namballa HK, Harding WW (2024) Natural Product-Inspired Dopamine Receptor Ligands. J Med Chem 67:12463\u201312484","journal-title":"J Med Chem"},{"key":"4351_CR52","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/ars.2005.7.1223","volume":"7","author":"R Dringen","year":"2005","unstructured":"Dringen R (2005) Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 7:1223\u20131233","journal-title":"Antioxid Redox Signal"},{"key":"4351_CR53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jnr.20280","volume":"79","author":"R Dringen","year":"2005","unstructured":"Dringen R, Pawlowski PG, Hirrlinger J (2005) Peroxide detoxification by brain cells. J Neurosci Res 79:157\u2013165","journal-title":"J Neurosci Res"},{"key":"4351_CR54","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3390\/jcm12124012","volume":"12","author":"W Drozdz","year":"2023","unstructured":"Drozdz W et al (2023) Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review. J Clin Med 12:4012","journal-title":"J Clin Med"},{"key":"4351_CR55","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3390\/molecules28062536","volume":"28","author":"A Duda-Chodak","year":"2023","unstructured":"Duda-Chodak A, Tarko T (2023) Possible side effects of polyphenols and their interactions with medicines. Molecules 28:2536","journal-title":"Molecules"},{"key":"4351_CR56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/acps.13416","volume":"146","author":"C Dunleavy","year":"2022","unstructured":"Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S (2022) Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand 146:6\u201320","journal-title":"Acta Psychiatr Scand"},{"key":"4351_CR57","doi-asserted-by":"crossref","unstructured":"Earl M (2017) Understanding Mental Disorders: Your Guide to DSM-5, by American Psychiatric Association with Forward by Patrick J. Kennedy: Washington, DC, American Psychiatric Publishing, 2015, 370 pp., $24.95 (softcover), ISBN 978\u201358562\u20131. Taylor & Francis. Journal of Consumer Health on the Internet 21:103-104","DOI":"10.1080\/15398285.2017.1280352"},{"key":"4351_CR58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0079-6468(05)43004-0","volume":"43","author":"RM Eglen","year":"2005","unstructured":"Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105\u2013136","journal-title":"Prog Med Chem"},{"key":"4351_CR59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41398-021-01273-2","volume":"11","author":"DW Eyles","year":"2021","unstructured":"Eyles DW (2021) How do established developmental risk-factors for schizophrenia change the way the brain develops? Transl Psychiatry 11:158","journal-title":"Transl Psychiatry"},{"key":"4351_CR60","doi-asserted-by":"crossref","unstructured":"Fan H-R et al (2018) Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity. eBioMedicine 34: 201\u2013213","DOI":"10.1016\/j.ebiom.2018.07.031"},{"key":"4351_CR61","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M et al (2023) Effects of Environmental Factors and Epigenetic on Health and the Development of Diseases. Kindle 3:1\u2013186","journal-title":"Kindle"},{"key":"4351_CR62","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuroscience.2014.05.040","volume":"282","author":"P Faure","year":"2014","unstructured":"Faure P, Tolu S, Valverde S, Naud\u00e9 J (2014) Role of nicotinic acetylcholine receptors in regulating dopamine neuron activity. Neuroscience 282:86\u2013100","journal-title":"Neuroscience"},{"key":"4351_CR63","doi-asserted-by":"crossref","first-page":"694863","DOI":"10.3389\/fpsyt.2021.694863","volume":"12","author":"A Fiorentini","year":"2021","unstructured":"Fiorentini A et al (2021) Substance-induced psychoses: an updated literature review. Front Psych 12:694863","journal-title":"Front Psych"},{"key":"4351_CR64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","volume":"74","author":"J Flatow","year":"2013","unstructured":"Flatow J, Buckley P, Miller BJ (2013) Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 74:400\u2013409","journal-title":"Biol Psychiatry"},{"key":"4351_CR65","doi-asserted-by":"crossref","unstructured":"Fond G et al (2023) Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs. BMJ Ment Health 26:e300771","DOI":"10.1136\/bmjment-2023-300771"},{"key":"4351_CR66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/npr2.12112","volume":"40","author":"Y Fujita","year":"2020","unstructured":"Fujita Y et al (2020) Dietary intake of glucoraphanin during pregnancy and lactation prevents the behavioral abnormalities in the offspring after maternal immune activation. Neuropsychopharmacology Reports 40:268\u2013274","journal-title":"Neuropsychopharmacology Reports"},{"key":"4351_CR67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12888-019-2059-x","volume":"19","author":"A Ghaderi","year":"2019","unstructured":"Ghaderi A et al (2019a) Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. BMC Psychiatry 19:77","journal-title":"BMC Psychiatry"},{"key":"4351_CR68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00228-018-2595-1","volume":"75","author":"A Ghaderi","year":"2019","unstructured":"Ghaderi A, Bussu A, Tsang C, Jafarnejad S (2019b) Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Eur J Clin Pharmacol 75:289\u2013301","journal-title":"Eur J Clin Pharmacol"},{"key":"4351_CR69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1986.tb11123.x","volume":"89","author":"A Giachetti","year":"1986","unstructured":"Giachetti A, Giraldo E, Ladinsky H, Montagna E (1986) Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol 89:83\u201390","journal-title":"Br J Pharmacol"},{"key":"4351_CR70","doi-asserted-by":"crossref","unstructured":"Gliwinska A et al (2023) The Role of Brain-Derived Neurotrophic Factor (BDNF) in Diagnosis and Treatment of Epilepsy, Depression, Schizophrenia, Anorexia Nervosa and Alzheimer's Disease as Highly Drug-Resistant Diseases: A Narrative Review. Brain Sci 13:163","DOI":"10.3390\/brainsci13020163"},{"key":"4351_CR71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1176\/appi.ajp.161.9.1705","volume":"161","author":"DC Goff","year":"2004","unstructured":"Goff DC et al (2004) Folate, Homocysteine, and Negative Symptoms in Schizophrenia. Am J Psychiatry 161:1705\u20131708","journal-title":"Am J Psychiatry"},{"key":"4351_CR72","doi-asserted-by":"crossref","unstructured":"Gomes FV et al (2014) Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol 18:pyu041","DOI":"10.1093\/ijnp\/pyu041"},{"key":"4351_CR73","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.3390\/nu15153454","volume":"15","author":"I Grabska-Koby\u0142ecka","year":"2023","unstructured":"Grabska-Koby\u0142ecka I et al (2023) Polyphenols and their impact on the prevention of neurodegenerative diseases and development. Nutrients 15:3454","journal-title":"Nutrients"},{"key":"4351_CR74","unstructured":"Granger K, Barnett J (2022) Schizophrenic Disorder Treatment using Combination Therapy. U.S. Patent Application No. 17\/755,084"},{"key":"4351_CR75","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1523\/JNEUROSCI.3523-14.2015","volume":"35","author":"M Guidi","year":"2015","unstructured":"Guidi M, Kumar A, Foster TC (2015) Impaired attention and synaptic senescence of the prefrontal cortex involves redox regulation of NMDA receptors. J Neurosci 35:3966\u20133977","journal-title":"J Neurosci"},{"key":"4351_CR76","unstructured":"Gummerson DM (2023) Modelling Prenatal Hypoxia As A Risk Factor For Schizophrenia Vulnerability In Patient-Derived Cerebral Organoids. Dissertation, The University of Western Ontario (Canada)"},{"key":"4351_CR77","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/FBP.0000000000000651","volume":"32","author":"S G\u00fcneri","year":"2021","unstructured":"G\u00fcneri S, Scheel-Kr\u00fcger J, Luo F (2021) Evaluation of acute and chronic nociception in subchronically administered MK-801-induced rat model of schizophrenia. Behav Pharmacol 32:571\u2013580","journal-title":"Behav Pharmacol"},{"key":"4351_CR78","doi-asserted-by":"crossref","first-page":"16621","DOI":"10.1073\/pnas.0706778104","volume":"104","author":"R Gysin","year":"2007","unstructured":"Gysin R et al (2007) Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A 104:16621\u201316626","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4351_CR79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41398-020-00919-x","volume":"10","author":"TD Habtewold","year":"2020","unstructured":"Habtewold TD et al (2020) A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits. Transl Psychiatry 10:244","journal-title":"Transl Psychiatry"},{"key":"4351_CR80","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neubiorev.2020.04.012","volume":"113","author":"FL Haddad","year":"2020","unstructured":"Haddad FL, Patel SV, Schmid S (2020) Maternal immune activation by poly I: C as a preclinical model for neurodevelopmental disorders: a focus on autism and schizophrenia. Neurosci Biobehav Rev 113:546\u2013567","journal-title":"Neurosci Biobehav Rev"},{"key":"4351_CR81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrn.2015.19","volume":"17","author":"GE Hardingham","year":"2016","unstructured":"Hardingham GE, Do KQ (2016) Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci 17:125\u2013134","journal-title":"Nat Rev Neurosci"},{"key":"4351_CR82","doi-asserted-by":"crossref","first-page":"1015835","DOI":"10.3389\/fphar.2022.1015835","volume":"13","author":"SSU Hassan","year":"2022","unstructured":"Hassan SSU et al (2022) The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress. Front Pharmacol 13:1015835","journal-title":"Front Pharmacol"},{"key":"4351_CR83","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/biof.1932","volume":"49","author":"S Hassanizadeh","year":"2023","unstructured":"Hassanizadeh S, Shojaei M, Bagherniya M, Orekhov AN, Sahebkar A (2023) Effect of nano-curcumin on various diseases: a comprehensive review of clinical trials. BioFactors 49:512\u2013533","journal-title":"BioFactors"},{"key":"4351_CR84","first-page":"2130","volume":"37","author":"G He","year":"2012","unstructured":"He G, Xu Y, Wu L, Zhang Z (2012) Regulating effect of Ginkgo biloba extract 50 on hippocampal inflammation-related cytokines in senile rats. Zhongguo Zhong Yao Za Zhi 37:2130\u20132134","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"4351_CR85","doi-asserted-by":"crossref","unstructured":"Hermle L, Kraehenmann R (2018) Experimental psychosis research and schizophrenia\u2014similarities and dissimilarities in psychopathology. In: Halberstadt, A.L., Vollenweider, F.X., Nichols, D.E. (eds) Behav Neurobiol Psychedelic Drugs 313\u2013332. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin, Heidelberg","DOI":"10.1007\/7854_2016_460"},{"key":"4351_CR86","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1017\/S0033291723000880","volume":"53","author":"C Hjorth\u00f8j","year":"2023","unstructured":"Hjorth\u00f8j C et al (2023) Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med 53:7322\u20137328","journal-title":"Psychol Med"},{"key":"4351_CR87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/NMD.0000000000000782","volume":"206","author":"HR Hoenders","year":"2018","unstructured":"Hoenders HR et al (2018) Natural medicines for psychotic disorders: a systematic review. J Nerv Ment Dis 206:81\u2013101","journal-title":"J Nerv Ment Dis"},{"key":"4351_CR88","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","volume":"383","author":"OD Howes","year":"2014","unstructured":"Howes OD, Murray RM (2014) Schizophrenia: an integrated sociodevelopmental-cognitive model. The Lancet 383:1677\u20131687","journal-title":"The Lancet"},{"key":"4351_CR89","doi-asserted-by":"crossref","first-page":"114336","DOI":"10.1016\/j.intimp.2025.114336","volume":"151","author":"Z Huang","year":"2025","unstructured":"Huang Z et al (2025) Urolithin A ameliorates schizophrenia-like behaviors and cognitive impairments in female rats by modulating NLRP3 signaling. Int Immunopharmacol 151:114336","journal-title":"Int Immunopharmacol"},{"key":"4351_CR90","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biopsych.2020.11.025","volume":"90","author":"L Hubbard","year":"2021","unstructured":"Hubbard L et al (2021) Rare copy number variants are associated with poorer cognition in schizophrenia. Biol Psychiat 90:28\u201334","journal-title":"Biol Psychiat"},{"key":"4351_CR91","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7150\/ijbs.23247","volume":"14","author":"G Hussain","year":"2018","unstructured":"Hussain G et al (2018) Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders. Int J Biol Sci 14:341\u2013357","journal-title":"Int J Biol Sci"},{"key":"4351_CR92","doi-asserted-by":"crossref","first-page":"204512532095711","DOI":"10.1177\/2045125320957119","volume":"10","author":"C Hynes","year":"2020","unstructured":"Hynes C et al (2020) Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort. Therapeutic Adv Psychopharmacol 10:2045125320957119","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"4351_CR93","doi-asserted-by":"crossref","unstructured":"\u0130nce Palamutoglu M, K\u00f6se G, Bas M (2024) Probiotics and Prebiotics Affecting Mental and Gut Health. Healthcare 12:510","DOI":"10.3390\/healthcare12050510"},{"key":"4351_CR94","doi-asserted-by":"crossref","unstructured":"Ivanova Stojcheva E, Quintela JC (2022) The effectiveness of Rhodiola rosea L. preparations in alleviating various aspects of life-stress symptoms and stress-induced conditions\u2014encouraging clinical evidence. Molecules 27:3902","DOI":"10.3390\/molecules27123902"},{"key":"4351_CR95","doi-asserted-by":"crossref","first-page":"663854","DOI":"10.3389\/fcell.2021.663854","volume":"9","author":"M Jahangir","year":"2021","unstructured":"Jahangir M, Zhou J-S, Lang B, Wang X-P (2021) GABAergic system dysfunction and challenges in schizophrenia research. Front Cell Dev Biol 9:663854","journal-title":"Front Cell Dev Biol"},{"key":"4351_CR96","doi-asserted-by":"crossref","unstructured":"Jawanjal N, Chatterjee I (2021) Genetic Study of Schizophrenia and Role of Computational Genomics in Mental Healthcare. Knowledge Modelling and Big Data Analytics in Healthcare. p 183\u2013202. CRC Press","DOI":"10.1201\/9781003142751-13"},{"key":"4351_CR97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2017.09.014","volume":"126","author":"SJ Jeon","year":"2017","unstructured":"Jeon SJ et al (2017) Maslinic acid ameliorates NMDA receptor blockade-induced schizophrenia-like behaviors in mice. Neuropharmacology 126:168\u2013178","journal-title":"Neuropharmacology"},{"key":"4351_CR98","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.1073\/pnas.1307925110","volume":"110","author":"AW Johnson","year":"2013","unstructured":"Johnson AW et al (2013) Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proc Natl Acad Sci U S A 110:12462\u201312467","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4351_CR99","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00213-019-05431-9","volume":"237","author":"P Ju","year":"2020","unstructured":"Ju P et al (2020) The protective effects of Mogroside V and its metabolite 11-oxo-mogrol of intestinal microbiota against MK801-induced neuronal damages. Psychopharmacology 237:1011\u20131026","journal-title":"Psychopharmacology"},{"key":"4351_CR100","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/nu15204391","volume":"15","author":"S Ju","year":"2023","unstructured":"Ju S et al (2023) The gut\u2013brain axis in schizophrenia: The implications of the gut microbiome and SCFA production. Nutrients 15:4391","journal-title":"Nutrients"},{"key":"4351_CR101","doi-asserted-by":"crossref","unstructured":"Kadakia A, Brady BL, Dembek C, Williams GR, Kent JM (2022) Burden of EPS in Commercial Patients With Schizophrenia Initiating Atypical Antipsychotics. Am J Managed Care 28","DOI":"10.37765\/ajmc.2022.89163"},{"key":"4351_CR102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.psychres.2009.01.013","volume":"175","author":"A Kale","year":"2010","unstructured":"Kale A et al (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res 175:47\u201353","journal-title":"Psychiatry Res"},{"key":"4351_CR103","doi-asserted-by":"crossref","first-page":"S615","DOI":"10.33549\/physiolres.935501","volume":"73","author":"I Kawikova","year":"2024","unstructured":"Kawikova I et al (2024) Perinatal Hypoxia and Immune System Activation in Schizophrenia Pathogenesis: Critical Considerations During COVID-19 Pandemic. Physiol Res 73:S615","journal-title":"Physiol Res"},{"key":"4351_CR104","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ijbiomac.2022.06.001","volume":"213","author":"A Khan","year":"2022","unstructured":"Khan A et al (2022) Identification of novel prolyl oligopeptidase inhibitors from resin of Boswella papyrifera (Del.) Hochst. and their mechanism: Virtual and biochemical studies. Int J Biol Macromol 213:751\u2013767","journal-title":"Int J Biol Macromol"},{"key":"4351_CR105","unstructured":"Kim S (2022) Comparison of Treatment Effectiveness of Clozapine, Haloperidol, and Chlorpromazine for Schizophrenia. Helix: The Capstone Research Journal of Ivy Collegiate School: 2021\u20132022 2:113"},{"key":"4351_CR106","doi-asserted-by":"crossref","first-page":"113285","DOI":"10.1016\/j.psychres.2020.113285","volume":"291","author":"MM Koola","year":"2020","unstructured":"Koola MM, Looney SW, Hong H, Pillai A, Hou W (2020) Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement. Psychiatry Res 291:113285","journal-title":"Psychiatry Res"},{"key":"4351_CR107","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1007\/s12035-023-03329-4","volume":"60","author":"I Korczowska-\u0141\u0105cka","year":"2023","unstructured":"Korczowska-\u0141\u0105cka I et al (2023) Selected biomarkers of oxidative stress and energy metabolism disorders in neurological diseases. Mol Neurobiol 60:4132\u20134149","journal-title":"Mol Neurobiol"},{"key":"4351_CR108","volume-title":"Psychiatrie: ein kurzes Lehrbuch f\u00fcr Studirende und Aerzte","author":"E Kraepelin","year":"1893","unstructured":"Kraepelin E (1893) Psychiatrie: ein kurzes Lehrbuch f\u00fcr Studirende und Aerzte. Abel, Heidelberg, Germany"},{"key":"4351_CR109","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3390\/ijms25042294","volume":"25","author":"W Krzy\u015bciak","year":"2024","unstructured":"Krzy\u015bciak W et al (2024) Association of blood metabolomics biomarkers with brain metabolites and patient-reported outcomes as a new approach in individualized diagnosis of schizophrenia. Int J Mol Sci 25:2294","journal-title":"Int J Mol Sci"},{"key":"4351_CR110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/JCP.0000000000001012","volume":"39","author":"S Kucukgoncu","year":"2019","unstructured":"Kucukgoncu S, Guloksuz S, Tek C (2019) Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia: A Double-Blind, Placebo-Controlled Pilot Trial. J Clin Psychopharmacol 39:182\u2013184","journal-title":"J Clin Psychopharmacol"},{"key":"4351_CR111","doi-asserted-by":"crossref","unstructured":"Kuo HY, Liu FC (2019) Synaptic Wiring of Corticostriatal Circuits in Basal Ganglia: Insights into the Pathogenesis of Neuropsychiatric Disorders. eNeuro 6:ENEURO.0076-19.2019","DOI":"10.1523\/ENEURO.0076-19.2019"},{"key":"4351_CR112","doi-asserted-by":"crossref","unstructured":"K\u00fcpeli Akkol E et al (2021) Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases. Front Pharmacol 12","DOI":"10.3389\/fphar.2021.669638"},{"key":"4351_CR113","doi-asserted-by":"crossref","unstructured":"Ku\u015fman A (2024) Aetiology and Risk Factors of Schizophrenia. In: C. Hocaoglu (ed.) New Approaches to the Management and Diagnosis of Schizophrenia. IntechOpen, Rijeka, Croatia:1","DOI":"10.5772\/intechopen.1005178"},{"key":"4351_CR114","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.2174\/1570159X19666210809100357","volume":"20","author":"TT Le","year":"2022","unstructured":"Le TT, McGrath SR, Fasinu PS (2022) Herb-drug interactions in neuropsychiatric pharmacotherapy\u2013a review of clinically relevant findings. Curr Neuropharmacol 20:1736","journal-title":"Curr Neuropharmacol"},{"key":"4351_CR115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","volume":"35","author":"DA Lewis","year":"2012","unstructured":"Lewis DA, Curley AA, Glausier JR, Volk DW (2012) Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35:57\u201367","journal-title":"Trends Neurosci"},{"key":"4351_CR116","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0074-7742(06)78004-7","volume":"78","author":"DA Lewis","year":"2007","unstructured":"Lewis DA, Hashimoto T (2007) Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol 78:109\u2013131","journal-title":"Int Rev Neurobiol"},{"key":"4351_CR117","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312\u2013324","journal-title":"Nat Rev Neurosci"},{"key":"4351_CR118","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41537-024-00485-x","volume":"10","author":"D Li","year":"2024","unstructured":"Li D, Pan Q, Xiao Y, Hu K (2024a) Advances in the study of phencyclidine-induced schizophrenia-like animal models and the underlying neural mechanisms. Schizophrenia 10:65","journal-title":"Schizophrenia"},{"key":"4351_CR119","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00406-021-01359-4","volume":"272","author":"M Li","year":"2022","unstructured":"Li M et al (2022) Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 272:633\u2013642","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4351_CR120","doi-asserted-by":"crossref","first-page":"1425839","DOI":"10.3389\/fnut.2024.1425839","volume":"11","author":"S Li","year":"2024","unstructured":"Li S, Wang Z, Liu G, Chen M (2024b) Neurodegenerative diseases and catechins: (\u2212)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress. Front Nutr 11:1425839","journal-title":"Front Nutr"},{"key":"4351_CR121","volume-title":"Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework 63:205\u2013240","author":"E Lipner","year":"2022","unstructured":"Lipner E, O\u2019Brien KJ, Pike MR, Ered A, Ellman LM (2022) Environmental risk factors and cognitive outcomes in psychosis: Pre-, perinatal, and early life adversity. In: Barch DM, Young JW (eds) Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework 63:205\u2013240. Springer International Publishing, Cham"},{"key":"4351_CR122","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2021.05.010","volume":"232","author":"AJ Lisoway","year":"2021","unstructured":"Lisoway AJ, Chen CC, Zai CC, Tiwari AK, Kennedy JL (2021) Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. Schizophr Res 232:112\u2013124","journal-title":"Schizophr Res"},{"key":"4351_CR123","doi-asserted-by":"crossref","first-page":"148931","DOI":"10.1016\/j.brainres.2024.148931","volume":"1835","author":"B Liu","year":"2024","unstructured":"Liu B et al (2024) Function and mechanism exploring of icariin in schizophrenia through network pharmacology. Brain Res 1835:148931","journal-title":"Brain Res"},{"key":"4351_CR124","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.sjbs.2020.11.037","volume":"28","author":"PT Lum","year":"2021","unstructured":"Lum PT, Sekar M, Gan SH, Pandy V, Bonam SR (2021) Protective effect of mangiferin on memory impairment: A systematic review. Saudi Journal of Biological Sciences 28:917\u2013927","journal-title":"Saudi Journal of Biological Sciences"},{"key":"4351_CR125","doi-asserted-by":"crossref","first-page":"823977","DOI":"10.3389\/fdgth.2022.823977","volume":"4","author":"J Lutz","year":"2022","unstructured":"Lutz J, Offidani E, Taraboanta L, Lakhan SE, Campellone TR (2022) Appropriate controls for digital therapeutic clinical trials: a narrative review of control conditions in clinical trials of digital therapeutics (DTx) deploying psychosocial, cognitive, or behavioral content. Front Digital Health 4:823977","journal-title":"Front Digital Health"},{"key":"4351_CR126","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/JCP.0000000000001765","volume":"43","author":"C Magistri","year":"2022","unstructured":"Magistri C, Mellini C (2022) Clozapine-associated agranulocytosis: a systematic review. Is it really so frighteningly common? J Clin Psychopharmacol 43:527\u2013533","journal-title":"J Clin Psychopharmacol"},{"key":"4351_CR127","doi-asserted-by":"crossref","first-page":"25974","DOI":"10.1021\/acsomega.2c03291","volume":"7","author":"A Marino","year":"2022","unstructured":"Marino A, Battaglini M, Moles N, Ciofani G (2022) Natural antioxidant compounds as potential pharmaceutical tools against neurodegenerative diseases. ACS Omega 7:25974\u201325990","journal-title":"ACS Omega"},{"key":"4351_CR128","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","volume":"28","author":"G Martinotti","year":"2022","unstructured":"Martinotti G et al (2022) Atypical antipsychotic drugs in dual disorders: current evidence for clinical practice. Curr Pharm des 28:2241\u20132259","journal-title":"Curr Pharm des"},{"key":"4351_CR129","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2174\/1570159X21666230322160259","volume":"21","author":"F Matrisciano","year":"2023","unstructured":"Matrisciano F (2023) Functional Nutrition as Integrated Intervention for In-and Outpatient with Schizophrenia. Curr Neuropharmacol 21:2409\u20132423","journal-title":"Curr Neuropharmacol"},{"key":"4351_CR130","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1089\/ars.2010.3453","volume":"15","author":"D Matsuzawa","year":"2011","unstructured":"Matsuzawa D, Hashimoto K (2011) Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 15:2057\u20132065","journal-title":"Antioxid Redox Signal"},{"key":"4351_CR131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42:205\u2013220","journal-title":"Trends Neurosci"},{"key":"4351_CR132","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RS, McGuire PK (2023) Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry 28:1902\u20131918","journal-title":"Mol Psychiatry"},{"key":"4351_CR133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","volume":"19","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Krystal JH, Howes OD (2020) Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 19:15\u201333","journal-title":"World Psychiatry"},{"key":"4351_CR134","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67\u201376","journal-title":"Epidemiol Rev"},{"key":"4351_CR135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/antiox12030663","volume":"12","author":"J Melrose","year":"2023","unstructured":"Melrose J (2023) The potential of flavonoids and flavonoid metabolites in the treatment of neurodegenerative pathology in disorders of cognitive decline. Antioxidants 12:663","journal-title":"Antioxidants"},{"key":"4351_CR136","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41380-021-01420-7","volume":"27","author":"AK Merikangas","year":"2022","unstructured":"Merikangas AK et al (2022) What genes are differentially expressed in individuals with schizophrenia? A systematic review. Mol Psychiatry 27:1373\u20131383","journal-title":"Mol Psychiatry"},{"key":"4351_CR137","doi-asserted-by":"crossref","first-page":"651720","DOI":"10.3389\/fphar.2021.651720","volume":"12","author":"E Micaglio","year":"2021","unstructured":"Micaglio E et al (2021) Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Front Pharmacol 12:651720","journal-title":"Front Pharmacol"},{"key":"4351_CR138","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/WNF.0000000000000344","volume":"42","author":"C Miodownik","year":"2019","unstructured":"Miodownik C et al (2019) Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. Clin Neuropharmacol 42:117\u2013122","journal-title":"Clin Neuropharmacol"},{"key":"4351_CR139","doi-asserted-by":"crossref","first-page":"105200","DOI":"10.1016\/j.psyneuen.2021.105200","volume":"127","author":"B Misiak","year":"2021","unstructured":"Misiak B et al (2021) Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. Psychoneuroendocrinology 127:105200","journal-title":"Psychoneuroendocrinology"},{"key":"4351_CR140","doi-asserted-by":"crossref","first-page":"e22276","DOI":"10.1002\/syn.22276","volume":"77","author":"E M\u0131s\u0131r","year":"2023","unstructured":"M\u0131s\u0131r E, Akay GG (2023) Synaptic dysfunction in schizophrenia. Synapse 77:e22276","journal-title":"Synapse"},{"key":"4351_CR141","doi-asserted-by":"crossref","first-page":"112877","DOI":"10.1016\/j.biopha.2022.112877","volume":"149","author":"S Mitra","year":"2022","unstructured":"Mitra S et al (2022) Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action. Biomed Pharmacother 149:112877","journal-title":"Biomed Pharmacother"},{"key":"4351_CR142","doi-asserted-by":"crossref","first-page":"136249","DOI":"10.1016\/j.neulet.2021.136249","volume":"765","author":"AH Moghaddam","year":"2021","unstructured":"Moghaddam AH, Maboudi K, Bavaghar B, Sangdehi SRM, Zare M (2021) Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neurosci Lett 765:136249","journal-title":"Neurosci Lett"},{"key":"4351_CR143","doi-asserted-by":"crossref","first-page":"C11","DOI":"10.1530\/EJE-20-0607","volume":"183","author":"ME Molitch","year":"2020","unstructured":"Molitch ME (2020) Dopamine agonists and antipsychotics. Eur J Endocrinol 183:C11\u2013C13","journal-title":"Eur J Endocrinol"},{"key":"4351_CR144","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/eip.12859","volume":"14","author":"D Mongan","year":"2020","unstructured":"Mongan D, Ramesar M, F\u00f6cking M, Cannon M, Cotter D (2020) Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry 14:385\u2013397","journal-title":"Early Interv Psychiatry"},{"key":"4351_CR145","doi-asserted-by":"crossref","first-page":"113304","DOI":"10.1016\/j.bbr.2021.113304","volume":"409","author":"JC Morales-Medina","year":"2021","unstructured":"Morales-Medina JC, Aguilar-Alonso P, Di Cerbo A, Iannitti T, Flores G (2021) New insights on nitric oxide: Focus on animal models of schizophrenia. Behav Brain Res 409:113304","journal-title":"Behav Brain Res"},{"key":"4351_CR146","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1038\/s41380-022-01582-y","volume":"27","author":"M Morrens","year":"2022","unstructured":"Morrens M et al (2022) The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. Mol Psychiatry 27:3237\u20133246","journal-title":"Mol Psychiatry"},{"key":"4351_CR147","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/jpm14040391","volume":"14","author":"FEC Mosquera","year":"2024","unstructured":"Mosquera FEC, Guevara-Montoya MC, Serna-Ramirez V, Liscano Y (2024) Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI). J Personalized Med 14:391","journal-title":"J Personalized Med"},{"key":"4351_CR148","doi-asserted-by":"crossref","first-page":"15094","DOI":"10.3390\/ijms242015094","volume":"24","author":"A Mo\u021b\u0103\u021b\u0103ianu","year":"2023","unstructured":"Mo\u021b\u0103\u021b\u0103ianu A, \u0218erban G, Andone S (2023) The role of short-chain fatty acids in microbiota\u2013gut\u2013brain cross-talk with a focus on amyotrophic lateral sclerosis: a systematic review. Int J Mol Sci 24:15094","journal-title":"Int J Mol Sci"},{"key":"4351_CR149","first-page":"413","volume":"5","author":"B Mousavi","year":"2015","unstructured":"Mousavi B et al (2015) Safety evaluation of saffron stigma (Crocus sativus L.) aqueous extract and crocin in patients with schizophrenia. Avicenna J Phytomed 5:413\u2013419","journal-title":"Avicenna J Phytomed"},{"key":"4351_CR150","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00737-023-01409-x","volume":"27","author":"E Mu","year":"2024","unstructured":"Mu E, Gurvich C, Kulkarni J (2024) Estrogen and psychosis\u2014a review and future directions. Archives of Women\u2019s Mental Health 27:877\u2013885","journal-title":"Archives of Women's Mental Health"},{"key":"4351_CR151","doi-asserted-by":"crossref","unstructured":"Munawar N, Ahsan K, Ahmad A (2024) Chapter 11 - Natural molecules in the treatment of schizophrenia. In: M. R. d. Oliveira (ed.). Natural Molecules in Neuroprotection and Neurotoxicity. p 259\u2013280. Academic Press","DOI":"10.1016\/B978-0-443-23763-8.00011-7"},{"key":"4351_CR152","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3389\/fnins.2018.00825","volume":"12","author":"NN Nalivaeva","year":"2018","unstructured":"Nalivaeva NN, Turner AJ, Zhuravin IA (2018) Role of prenatal hypoxia in brain development, cognitive functions, and neurodegeneration. Front Neurosci 12:825","journal-title":"Front Neurosci"},{"key":"4351_CR153","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.schres.2021.11.006","volume":"242","author":"HA Nasrallah","year":"2021","unstructured":"Nasrallah HA (2021) Re-inventing the schizophrenia syndrome: The elusive\" theory of everything\". Schizophr Res 242:106\u2013108","journal-title":"Schizophr Res"},{"key":"4351_CR154","doi-asserted-by":"crossref","first-page":"307","DOI":"10.47162\/RJME.63.2.03","volume":"63","author":"MG N\u0103stase","year":"2022","unstructured":"N\u0103stase MG, Vlaicu I, Trifu SC (2022) Genetic polymorphism and neuroanatomical changes in schizophrenia. Rom J Morphol Embryol 63:307","journal-title":"Rom J Morphol Embryol"},{"key":"4351_CR155","doi-asserted-by":"crossref","first-page":"173823","DOI":"10.1016\/j.pbb.2024.173823","volume":"242","author":"S Nikolaus","year":"2024","unstructured":"Nikolaus S et al (2024) 2, 5-Dimethoxy-4-iodoamphetamine and altanserin induce region-specific shifts in dopamine and serotonin metabolization pathways in the rat brain. Pharmacol Biochem Behav 242:173823","journal-title":"Pharmacol Biochem Behav"},{"key":"4351_CR156","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3390\/plants11192667","volume":"11","author":"CA Odebunmi","year":"2022","unstructured":"Odebunmi CA et al (2022) Ethnobotanical Survey of Medicinal Plants Used in the Treatment of COVID-19 and Related Respiratory Infections in Ogbomosho South and North Local Government Areas, Oyo State. Nigeria Plants 11:2667","journal-title":"Nigeria Plants"},{"key":"4351_CR157","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.sajb.2022.11.047","volume":"152","author":"F Olawale","year":"2023","unstructured":"Olawale F, Adetunji TL, Adetunji AE, Iwaloye O, Folorunso IM (2023) The therapeutic value of alstonine: An updated review. S Afr J Bot 152:288\u2013295","journal-title":"S Afr J Bot"},{"key":"4351_CR158","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.3390\/jcm11175040","volume":"11","author":"L Orsolini","year":"2022","unstructured":"Orsolini L, Pompili S, Volpe U (2022) Schizophrenia: a narrative review of etiopathogenetic, diagnostic and treatment aspects. J Clin Med 11:5040","journal-title":"J Clin Med"},{"key":"4351_CR159","doi-asserted-by":"crossref","first-page":"19","DOI":"10.17816\/CP132","volume":"3","author":"S Oskolkova","year":"2022","unstructured":"Oskolkova S (2022) Schizophrenia: a narrative review of etiological and diagnostic issues. Consortium Psychiatricum 3:19","journal-title":"Consortium Psychiatricum"},{"key":"4351_CR160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1538\/expanim.17-0050","volume":"66","author":"V Pandy","year":"2017","unstructured":"Pandy V, Vijeepallam K (2017) Antipsychotic-like activity of scopoletin and rutin against the positive symptoms of schizophrenia in mouse models. Exp Anim 66:417\u2013423","journal-title":"Exp Anim"},{"key":"4351_CR161","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuropharm.2014.06.025","volume":"86","author":"SJ Park","year":"2014","unstructured":"Park SJ et al (2014) Oleanolic acid attenuates MK-801-induced schizophrenia-like behaviors in mice. Neuropharmacology 86:49\u201356","journal-title":"Neuropharmacology"},{"key":"4351_CR162","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.3390\/ijms21113879","volume":"21","author":"YH Park","year":"2020","unstructured":"Park YH et al (2020) Omega-3 fatty acid-type docosahexaenoic acid protects against A\u03b2-mediated mitochondrial deficits and pathomechanisms in Alzheimer\u2019s disease-related animal model. Int J Mol Sci 21:3879","journal-title":"Int J Mol Sci"},{"key":"4351_CR163","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D (2014) Schizophrenia: overview and treatment options. Pharmacy and Therapeutics 39:638","journal-title":"Pharmacy and Therapeutics"},{"key":"4351_CR164","doi-asserted-by":"crossref","first-page":"742058","DOI":"10.3389\/fpsyt.2021.742058","volume":"12","author":"J-C Pei","year":"2021","unstructured":"Pei J-C, Luo D-Z, Gau S-S, Chang C-Y, Lai W-S (2021) Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia. Front Psych 12:742058","journal-title":"Front Psych"},{"key":"4351_CR165","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.3390\/nu16244368","volume":"16","author":"B Pekdemir","year":"2024","unstructured":"Pekdemir B et al (2024) Mechanisms and Potential Benefits of Neuroprotective Agents in Neurological Health. Nutrients 16:4368","journal-title":"Nutrients"},{"key":"4351_CR166","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","volume":"24","author":"M Pirmohamed","year":"2023","unstructured":"Pirmohamed M (2023) Pharmacogenomics: current status and future perspectives. Nat Rev Genet 24:350\u2013362","journal-title":"Nat Rev Genet"},{"key":"4351_CR167","doi-asserted-by":"crossref","first-page":"113101","DOI":"10.1016\/j.bbr.2020.113101","volume":"402","author":"TR Prestwood","year":"2021","unstructured":"Prestwood TR et al (2021) Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res 402:113101","journal-title":"Behav Brain Res"},{"key":"4351_CR168","doi-asserted-by":"crossref","unstructured":"Qu S et al (2024) Gut microbiota modulates neurotransmitter and gut-brain signaling. Microbiol Res 287","DOI":"10.1016\/j.micres.2024.127858"},{"key":"4351_CR169","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s11064-022-03798-4","volume":"48","author":"R Rabiee","year":"2023","unstructured":"Rabiee R, Hosseini Hooshiar S, Ghaderi A, Jafarnejad S (2023) Schizophrenia, curcumin and minimizing side effects of antipsychotic drugs: possible mechanisms. Neurochem Res 48:713\u2013724","journal-title":"Neurochem Res"},{"key":"4351_CR170","doi-asserted-by":"crossref","unstructured":"Raju NR et al (2023) Chapter 4 - Effects of medicinal plants and phytochemicals on schizophrenia. Phytochemical Drug Discovery for Central Nervous System Disorders (eds C. Egbuna and M. Rudrapal). Biochemistry and Therapeutic Effects: 81\u2013136","DOI":"10.1002\/9781119794127.ch4"},{"key":"4351_CR171","doi-asserted-by":"crossref","first-page":"646287","DOI":"10.3389\/fphar.2021.646287","volume":"12","author":"M Rasool","year":"2021","unstructured":"Rasool M et al (2021) Role of oxidative stress and the identification of biomarkers associated with thyroid dysfunction in schizophrenics. Front Pharmacol 12:646287","journal-title":"Front Pharmacol"},{"key":"4351_CR172","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3390\/ijms25063203","volume":"25","author":"C Ricardi","year":"2024","unstructured":"Ricardi C et al (2024) Beta-caryophyllene, a cannabinoid receptor type 2 selective agonist, in emotional and cognitive disorders. Int J Mol Sci 25:3203","journal-title":"Int J Mol Sci"},{"key":"4351_CR173","unstructured":"Rodr\u00edguez Prieto \u00c1 (2024) Nrg1 Signaling in the Development of Cortical Circuits: Molecular Basis of Schizophrenia. Dissertation, Universitat Polit\u00e8cnica de Val\u00e8ncia"},{"key":"4351_CR174","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3390\/jcm13102819","volume":"13","author":"J Rog","year":"2024","unstructured":"Rog J et al (2024) The Potential Role of the Ketogenic Diet in Serious Mental Illness: Current Evidence, Safety, and Practical Advice. J Clin Med 13:2819","journal-title":"J Clin Med"},{"key":"4351_CR175","doi-asserted-by":"crossref","first-page":"895668","DOI":"10.3389\/fphar.2022.895668","volume":"13","author":"A Saleem","year":"2022","unstructured":"Saleem A, Akhtar MF (2022) Alternative therapy of psychosis: Potential phytochemicals and drug targets in the management of schizophrenia. Front Pharmacol 13:895668","journal-title":"Front Pharmacol"},{"key":"4351_CR176","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ijnp\/pyaa006","volume":"23","author":"A Samaei","year":"2020","unstructured":"Samaei A et al (2020) Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. Int J Neuropsychopharmacol 23:775\u2013782","journal-title":"Int J Neuropsychopharmacol"},{"key":"4351_CR177","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.biopha.2018.04.082","volume":"103","author":"MA Santill\u00e1n-Urquiza","year":"2018","unstructured":"Santill\u00e1n-Urquiza MA et al (2018) Pharmacological interaction of Galphimia glauca extract and natural galphimines with Ketamine and Haloperidol on different behavioral tests. Biomed Pharmacother 103:879\u2013888","journal-title":"Biomed Pharmacother"},{"key":"4351_CR178","first-page":"068","volume":"3","author":"H Sasani","year":"2022","unstructured":"Sasani H, Erba\u015f O (2022) Understanding the Role of DISC1 in Psychiatric Disorders. J Experimental Basic Med Sci 3:068\u2013078","journal-title":"J Experimental Basic Med Sci"},{"key":"4351_CR179","doi-asserted-by":"crossref","first-page":"100191","DOI":"10.1016\/j.phyplu.2021.100191","volume":"2","author":"P Sasikumar","year":"2022","unstructured":"Sasikumar P, Aswathy M, Prem PT, Radhakrishnan KV, Chakrapani PSB (2022) Plant derived bioactive compounds and their potential to enhance adult neurogenesis. Phytomedicine plus 2:100191","journal-title":"Phytomedicine plus"},{"key":"4351_CR180","doi-asserted-by":"crossref","first-page":"e068652","DOI":"10.1136\/bmjopen-2022-068652","volume":"13","author":"MR Sass","year":"2023","unstructured":"Sass MR et al (2023) Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open 13:e068652","journal-title":"BMJ Open"},{"key":"4351_CR181","doi-asserted-by":"crossref","first-page":"106941","DOI":"10.1016\/j.cct.2022.106941","volume":"122","author":"VA Schoeps","year":"2022","unstructured":"Schoeps VA et al (2022) N-acetyl cysteine as a neuroprotective agent in progressive multiple sclerosis (NACPMS) trial: study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial. Contemp Clin Trials 122:106941","journal-title":"Contemp Clin Trials"},{"key":"4351_CR182","doi-asserted-by":"crossref","unstructured":"Schwartz DL (2016) Quercetin as an Augmentation Agent in Schizophrenia. J Clin Psychopharmacol 36:282-283","DOI":"10.1097\/JCP.0000000000000498"},{"key":"4351_CR183","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pnpbp.2017.11.001","volume":"82","author":"Z Sepehrmanesh","year":"2018","unstructured":"Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M (2018) Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 82:289\u2013296","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4351_CR184","unstructured":"Sethi S, Ford JM (2022) The role of ketogenic metabolic therapy on the brain in serious mental illness: a review. J Psychiatry Brain Sci 7:e220009"},{"key":"4351_CR185","doi-asserted-by":"crossref","first-page":"649395","DOI":"10.3389\/fmolb.2021.649395","volume":"8","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J et al (2021) Resveratrol-based nanoformulations as an emerging therapeutic strategy for cancer. Front Mol Biosci 8:649395","journal-title":"Front Mol Biosci"},{"key":"4351_CR186","doi-asserted-by":"crossref","first-page":"1201252","DOI":"10.3389\/fimmu.2023.1201252","volume":"14","author":"J Shen","year":"2023","unstructured":"Shen J et al (2023) Prognostic and immunomodulatory roles of schizophrenia-associated genes HTR2A, COMT, and PRODH in pan-cancer analysis and glioma survival prediction model. Front Immunol 14:1201252","journal-title":"Front Immunol"},{"key":"4351_CR187","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12906-025-04872-4","volume":"25","author":"L Shi","year":"2025","unstructured":"Shi L, Wang W, Jing C, Hu J, Liao X (2025) Berberine and health outcomes: an overview of systematic reviews. BMC Complementary Med Therapies 25:147","journal-title":"BMC Complementary Med Therapies"},{"key":"4351_CR188","doi-asserted-by":"crossref","first-page":"pyae005","DOI":"10.1093\/ijnp\/pyae005","volume":"27","author":"R Singh","year":"2024","unstructured":"Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G (2024) Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 27:pyae005","journal-title":"Int J Neuropsychopharmacol"},{"key":"4351_CR189","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M et al (2023) Incidence, prevalence, and global burden of schizophrenia-data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry 28:5319\u20135327","journal-title":"Mol Psychiatry"},{"key":"4351_CR190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fpsyt.2020.00613","volume":"11","author":"SF Sonnenschein","year":"2020","unstructured":"Sonnenschein SF, Gomes FV, Grace AA (2020) Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia. Front Psych 11:613","journal-title":"Front Psych"},{"key":"4351_CR191","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2174\/1570159X19666210712151556","volume":"19","author":"AB Speers","year":"2021","unstructured":"Speers AB, Cabey KA, Soumyanath A, Wright KM (2021) Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol 19:1468","journal-title":"Curr Neuropharmacol"},{"key":"4351_CR192","doi-asserted-by":"crossref","first-page":"17589","DOI":"10.1149\/10701.17589ecst","volume":"107","author":"T Srivastav","year":"2022","unstructured":"Srivastav T, Kapse A, Kalambe M, Deshpande S (2022) Overview of schizophrenia: a review article. ECS Trans 107:17589","journal-title":"ECS Trans"},{"key":"4351_CR193","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuroscience.2005.10.014","volume":"137","author":"P Steullet","year":"2006","unstructured":"Steullet P, Neijt HC, Cu\u00e9nod M, Do KQ (2006) Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137:807\u2013819","journal-title":"Neuroscience"},{"key":"4351_CR194","doi-asserted-by":"crossref","first-page":"152209","DOI":"10.1016\/j.comppsych.2020.152209","volume":"103","author":"X-J Sun","year":"2020","unstructured":"Sun X-J, Zhao X, Xie J-N, Wan H (2020) Crocin alleviates schizophrenia-like symptoms in rats by upregulating silent information regulator-1 and brain derived neurotrophic factor. Compr Psychiatry 103:152209","journal-title":"Compr Psychiatry"},{"key":"4351_CR195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbi.2020.04.034","volume":"88","author":"W Tang","year":"2020","unstructured":"Tang W et al (2020) Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome. Brain Behav Immun 88:529\u2013534","journal-title":"Brain Behav Immun"},{"key":"4351_CR196","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1038\/tp.2011.52","volume":"1","author":"J Tarabeux","year":"2011","unstructured":"Tarabeux J et al (2011) Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry 1:e55","journal-title":"Transl Psychiatry"},{"key":"4351_CR197","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1016\/j.bmc.2008.04.067","volume":"16","author":"T Tarrag\u00f3","year":"2008","unstructured":"Tarrag\u00f3 T et al (2008) Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem 16:7516\u20137524","journal-title":"Bioorg Med Chem"},{"key":"4351_CR198","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cmdc.200600303","volume":"2","author":"T Tarrago","year":"2007","unstructured":"Tarrago T, Kichik N, Segu\u00ed J, Giralt E (2007) The Natural Product Berberine is a Human Prolyl Oligopeptidase Inhibitor. ChemMedChem 2:354\u2013359","journal-title":"ChemMedChem"},{"key":"4351_CR199","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/IJPSYM.IJPSYM_322_17","volume":"40","author":"H Tharoor","year":"2018","unstructured":"Tharoor H, Mara S, Gopal S (2018) Role of Novel Dietary Supplement N-acetyl Cysteine in Treating Negative Symptoms in Schizophrenia: A 6-Month Follow-up Study. Indian J Psychol Med 40:139\u2013142","journal-title":"Indian J Psychol Med"},{"key":"4351_CR200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2012.12.026","volume":"242","author":"X Tian","year":"2013","unstructured":"Tian X et al (2013) The protective effect of hyperbaric oxygen and Ginkgo biloba extract on Abeta25-35-induced oxidative stress and neuronal apoptosis in rats. Behav Brain Res 242:1\u20138","journal-title":"Behav Brain Res"},{"key":"4351_CR201","doi-asserted-by":"crossref","first-page":"173412","DOI":"10.1016\/j.ejphar.2020.173412","volume":"886","author":"MS Uddin","year":"2020","unstructured":"Uddin MS et al (2020) Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration. Eur J Pharmacol 886:173412","journal-title":"Eur J Pharmacol"},{"key":"4351_CR202","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3177\/jnsv.70.252","volume":"70","author":"K Ueno","year":"2024","unstructured":"Ueno K et al (2024) Behavioral Dysfunctions Caused by Pyridoxamine Deficiency in Drosophila melanogaster. J Nutr Sci Vitaminol 70:252\u2013261","journal-title":"J Nutr Sci Vitaminol"},{"key":"4351_CR203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fnbeh.2019.00195","volume":"13","author":"B Vafadari","year":"2019","unstructured":"Vafadari B, Mitra S, Stefaniuk M, Kaczmarek L (2019) Psychosocial stress induces schizophrenia-like behavior in mice with reduced MMP-9 activity. Front Behav Neurosci 13:195","journal-title":"Front Behav Neurosci"},{"key":"4351_CR204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.52667\/2712-9179-2021-1-1-11-17","volume":"1","author":"EE Vaiman","year":"2021","unstructured":"Vaiman EE, Novitsky MA, Nasyrova RF (2021) Pharmacogenetics of chlorpromazine and its role in the development of antipsychotic-induced parkinsonism. Personalized Psychiatry Neurol 1:11\u201317","journal-title":"Personalized Psychiatry Neurol"},{"key":"4351_CR205","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.3390\/molecules28196861","volume":"28","author":"F Vartzoka","year":"2023","unstructured":"Vartzoka F, Ozenoglu E, Pitsikas N (2023) The nitric oxide (NO) donor molsidomine attenuates memory impairments induced by the D1\/D2 dopaminergic receptor agonist apomorphine in the rat. Molecules 28:6861","journal-title":"Molecules"},{"key":"4351_CR206","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamapsychiatry.2023.5371","volume":"81","author":"SS Vasileva","year":"2024","unstructured":"Vasileva SS et al (2024) Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia. JAMA Psychiat 81:292\u2013302","journal-title":"JAMA Psychiat"},{"key":"4351_CR207","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euroneuro.2020.08.009","volume":"39","author":"J Vazquez-Bourgon","year":"2020","unstructured":"Vazquez-Bourgon J et al (2020) A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: a pragmatic clinical trial in first episode psychosis patients. Eur Neuropsychopharmacol 39:46\u201355","journal-title":"Eur Neuropsychopharmacol"},{"key":"4351_CR208","first-page":"45094","volume":"84","author":"DI Velligan","year":"2023","unstructured":"Velligan DI, Rao S (2023) The epidemiology and global burden of schizophrenia. J Clin Psychiatry 84:45094","journal-title":"J Clin Psychiatry"},{"key":"4351_CR209","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/10799893.2020.1720242","volume":"40","author":"C Venkataramaiah","year":"2020","unstructured":"Venkataramaiah C (2020) Modulations in the ATPases during ketamine-induced schizophrenia and regulatory effect of \u201c3-(3, 4-dimethoxy phenyl) -1- (4-methoxyphenyl) prop-2-en-1-one\u201d: an in vivo and in silico studies. J Recept Signal Transduction 40:148\u2013156","journal-title":"J Recept Signal Transduction"},{"key":"4351_CR210","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.3390\/ijms252313190","volume":"25","author":"D-K Vo","year":"2024","unstructured":"Vo D-K, Trinh KTL (2024) Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis. Int J Mol Sci 25:13190","journal-title":"Int J Mol Sci"},{"key":"4351_CR211","first-page":"487","volume":"3","author":"K Volkan","year":"2020","unstructured":"Volkan K (2020) Schizophrenia: epidemiology, causes, neurobiology, pathophysiology, and treatment. J Health Med Sci 3:487\u2013521","journal-title":"J Health Med Sci"},{"key":"4351_CR212","unstructured":"Walgama K (2024) Schizophrenia cannot be understood simply in terms of a dysfunctional dopamine system. J Uva Clin Society 17:1-8"},{"key":"4351_CR213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1745-7254.2006.00255.x","volume":"27","author":"R Wang","year":"2006","unstructured":"Wang R, Yan H, Tang X-C (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27:1\u201326","journal-title":"Acta Pharmacol Sin"},{"key":"4351_CR214","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1089\/ars.2012.4907","volume":"18","author":"X Wang","year":"2013","unstructured":"Wang X, Pinto-Duarte A, Sejnowski TJ, Behrens MM (2013) How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia. Antioxid Redox Signal 18:1444\u20131462","journal-title":"Antioxid Redox Signal"},{"key":"4351_CR215","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJMra2404606","volume":"391","author":"EF Wijdicks","year":"2024","unstructured":"Wijdicks EF, Ropper AH (2024) Neuroleptic malignant syndrome. N Engl J Med 391:1130\u20131138","journal-title":"N Engl J Med"},{"key":"4351_CR216","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1096\/fj.09-143974","volume":"24","author":"EK Wirth","year":"2010","unstructured":"Wirth EK et al (2010) Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration. FASEB J 24:844\u2013852","journal-title":"FASEB J"},{"key":"4351_CR217","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.schres.2017.09.046","volume":"195","author":"JK Wynn","year":"2018","unstructured":"Wynn JK et al (2018) The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophr Res 195:572\u2013573","journal-title":"Schizophr Res"},{"key":"4351_CR218","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.1523\/JNEUROSCI.20-18-06888.2000","volume":"20","author":"B Xu","year":"2000","unstructured":"Xu B et al (2000a) The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 20:6888\u20136897","journal-title":"J Neurosci"},{"key":"4351_CR219","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0896-6273(00)81153-8","volume":"26","author":"B Xu","year":"2000","unstructured":"Xu B et al (2000b) Cortical degeneration in the absence of neurotrophin signaling: dendritic retraction and neuronal loss after removal of the receptor TrkB. Neuron 26:233\u2013245","journal-title":"Neuron"},{"key":"4351_CR220","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00213-018-5136-9","volume":"236","author":"F Xu","year":"2019","unstructured":"Xu F et al (2019) Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial. Psychopharmacology 236:1273\u20131279","journal-title":"Psychopharmacology"},{"key":"4351_CR221","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.2174\/1568026621666211201150217","volume":"21","author":"DK Yadav","year":"2021","unstructured":"Yadav DK (2021) Potential therapeutic strategies of phytochemicals in neurodegenerative disorders. Curr Top Med Chem 21:2814\u20132838","journal-title":"Curr Top Med Chem"},{"key":"4351_CR222","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1523\/JNEUROSCI.22-17-07580.2002","volume":"22","author":"MK Yamada","year":"2002","unstructured":"Yamada MK et al (2002) Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. J Neurosci 22:7580\u20137585","journal-title":"J Neurosci"},{"key":"4351_CR223","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.3390\/molecules25204613","volume":"25","author":"B Yang","year":"2020","unstructured":"Yang B, Dong Y, Wang F, Zhang Y (2020) Nanoformulations to enhance the bioavailability and physiological functions of polyphenols. Molecules 25:4613","journal-title":"Molecules"},{"key":"4351_CR224","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/157015907782793649","volume":"5","author":"K Yang","year":"2007","unstructured":"Yang K, Jin G, Wu J (2007) The neuropharmacology of (-)-stepholidine and its potential applications. Curr Neuropharmacol 5:289\u2013294","journal-title":"Curr Neuropharmacol"},{"key":"4351_CR225","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1089\/ars.2010.3603","volume":"15","author":"JK Yao","year":"2011","unstructured":"Yao JK, Keshavan MS (2011) Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 15:2011\u20132035","journal-title":"Antioxid Redox Signal"},{"key":"4351_CR226","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/med.22086","volume":"45","author":"N Ye","year":"2025","unstructured":"Ye N, Wang Q, Li Y, Zhen X (2025) Current emerging therapeutic targets and clinical investigational agents for schizophrenia: challenges and opportunities. Med Res Rev 45:755\u2013787","journal-title":"Med Res Rev"},{"key":"4351_CR227","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bcp.2013.06.031","volume":"86","author":"JW Young","year":"2013","unstructured":"Young JW, Geyer MA (2013) Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol 86:1122\u20131132","journal-title":"Biochem Pharmacol"},{"key":"4351_CR228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YPG.0000000000000245","volume":"30","author":"M Zamanpoor","year":"2020","unstructured":"Zamanpoor M (2020) Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatr Genet 30:1\u20139","journal-title":"Psychiatr Genet"},{"key":"4351_CR229","doi-asserted-by":"crossref","first-page":"1177524","DOI":"10.3389\/fnmol.2023.1177524","volume":"16","author":"Z Zhang","year":"2023","unstructured":"Zhang Z et al (2023) The month of walking alone and BDNF level differ between drug-naive first-episode schizophrenia patients and healthy controls. Front Mol Neurosci 16:1177524","journal-title":"Front Mol Neurosci"},{"key":"4351_CR230","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/npp.2010.240","volume":"36","author":"R Zhao-Shea","year":"2011","unstructured":"Zhao-Shea R et al (2011) Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology 36:1021\u20131032","journal-title":"Neuropsychopharmacology"},{"key":"4351_CR231","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00213-020-05634-5","volume":"237","author":"H Zhong","year":"2020","unstructured":"Zhong H et al (2020) Neonatal curcumin treatment restores hippocampal neurogenesis and improves autism-related behaviors in a mouse model of autism. Psychopharmacology 237:3539\u20133552","journal-title":"Psychopharmacology"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04351-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T11:14:32Z","timestamp":1761304472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04351-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":231,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4351"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04351-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}